

## **Hepatitis B Vaccine Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034**

Market Report | 2025-07-04 | 140 pages | Global Market Insights

### **AVAILABLE LICENSES:**

- Single User \$4850.00
- Multi User \$6050.00
- Enterprise User \$8350.00

### **Report description:**

The Global Hepatitis B Vaccine Market was valued at USD 6.7 billion in 2024 and is estimated to grow at a CAGR of 5.7% to reach USD 12 billion by 2034. The growth trajectory is largely influenced by the increasing number of hepatitis B cases worldwide, backed by government-backed vaccination campaigns and accelerated vaccine development efforts. National immunization programs and expanded public health awareness have led to greater access and uptake of vaccines across various age groups. Additionally, demand for more efficient and targeted solutions is pushing continuous innovation in vaccine formulation and manufacturing. Advances in recombinant technology and delivery mechanisms are contributing to higher efficacy, longer-lasting immunity, and reduced dosage requirements. As healthcare systems aim to reduce the burden of liver-related diseases, the market is witnessing stronger momentum for preventive vaccination, particularly among at-risk populations.

The rising preference for next-generation formulations that deliver robust and rapid immune responses further supports adoption globally. These advanced vaccines are being engineered with enhanced antigen stability, improved adjuvant systems, and optimized delivery methods to generate quicker and more sustained protection against hepatitis B. Unlike traditional formulations, next-gen vaccines aim to reduce the number of doses required for full immunity, making them more suitable for large-scale immunization campaigns, especially in regions with limited healthcare access. This innovation is particularly crucial for immunocompromised individuals and high-risk groups who may not respond effectively to conventional vaccines.

In 2024, the combination vaccines segment led the market with a value of USD 4.5 billion and is forecasted to reach USD 7.8 billion by 2034, growing at a CAGR of 5.5%. These multivalent vaccines combine hepatitis B protection with immunization against other infectious agents, reducing the number of injections required. This integrated approach improves patient compliance and simplifies vaccine schedules, especially for infants and children. As a result, combination vaccines have gained widespread adoption in pediatric healthcare, supported by both public and private immunization programs. Governments and providers increasingly opt for these vaccines due to their efficiency in administration, broader coverage, and cost advantages, helping raise vaccination rates across communities.

The male segment is expected to reach USD 7.1 billion by 2034. This is largely driven by biological and hormonal differences that increase the risk of chronic infection and liver-related complications in men. Testosterone has been shown to influence immune

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

response and virus persistence, placing males at a greater risk of prolonged hepatitis B infection. As a result, immunization programs have increasingly focused on adult men, with widespread availability of adult vaccine formulations supporting this trend. Growing awareness, better access to healthcare, and a push for preventive care continue to accelerate vaccine adoption in this segment.

North America Hepatitis B Vaccine Market was valued at USD 2.7 billion in 2024 and is projected to reach USD 4.7 billion by 2034 at a CAGR of 5.4% through 2034. The region remains a dominant force in the global hepatitis B vaccine landscape due to its advanced healthcare delivery systems and high public awareness. Strong infrastructure, along with extensive government-backed vaccination programs, has enabled both pediatric and adult immunization rates to remain consistently high. The burden of hepatitis B remains significant, especially in vulnerable populations, prompting sustained efforts toward widespread prevention and early immunization coverage in countries like the U.S. and Canada.

Key market players include Serum Institute of India, VBI Vaccines, Sanofi, Biological E, YS Biopharma, GSK, Shenzhen Kangtai Biological Products, Bharat Biotech, Dynavax Technologies, Merck, and Gilead Sciences. To strengthen their market position, companies in the hepatitis B vaccine segment are focusing on product innovation, expanding their global distribution networks, and engaging in strategic partnerships.

Leading players are investing heavily in R&D to develop next-generation vaccines with improved safety profiles and stronger immunogenicity. Many are leveraging combination vaccine platforms to increase coverage and appeal to broader healthcare systems. Collaborations with government health agencies, NGOs, and international organizations are also enabling smoother vaccine rollouts in emerging markets.

□

## **Table of Contents:**

### Report Content

#### Chapter 1 Methodology and Scope

##### 1.1 Market scope and definition

##### 1.2 Research design

###### 1.2.1 Research approach

###### 1.2.2 Data collection methods

##### 1.3 Data mining sources

###### 1.3.1 Global

###### 1.3.2 Regional/Country

##### 1.4 Base estimates and calculations

###### 1.4.1 Base year calculation

###### 1.4.2 Key trends for market estimation

##### 1.5 Primary research and validation

###### 1.5.1 Primary sources

##### 1.6 Forecast model

##### 1.7 Research assumptions and limitations

#### Chapter 2 Executive Summary

##### 2.1 Industry 360 synopsis

##### 2.2 Key market trends

###### 2.2.1 Regional

###### 2.2.2 Vaccine type

###### 2.2.3 Age group

###### 2.2.4 Gender

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 2.2.5 End use
- 2.3 CXO perspectives: Strategic imperatives
  - 2.3.1 Key decision points for industry executives
  - 2.3.2 Critical success factors for market players
- 2.4 Future outlook and strategic recommendations

## Chapter 3 Industry Insights

- 3.1 Industry ecosystem analysis
  - 3.1.1 Supplier landscape
  - 3.1.2 Value addition at each stage
  - 3.1.3 Factors affecting the value chain
- 3.2 Industry impact forces
  - 3.2.1 Growth drivers
    - 3.2.1.1 Rising prevalence of liver diseases
    - 3.2.1.2 Growing immunization coverage programs
    - 3.2.1.3 Advancements in vaccine formulation and production efficiency
    - 3.2.1.4 Increasing R&D investment and activities
  - 3.2.2 Industry pitfalls and challenges
    - 3.2.2.1 Stringent regulatory approval processes
    - 3.2.2.2 High cost of storage and transportation of vaccine
  - 3.2.3 Market opportunities
    - 3.2.3.1 Growing public-private partnerships for vaccine distribution
    - 3.2.3.2 Expanding adult vaccination programs
- 3.3 Growth potential analysis
- 3.4 Pipeline analysis
- 3.5 Regulatory landscape
- 3.6 Technological advancements
- 3.7 Future market trends
- 3.8 Porter's analysis
- 3.9 PESTEL analysis

## Chapter 4 Competitive Landscape, 2024

- 4.1 Introduction
- 4.2 Company matrix analysis
- 4.3 Company market share analysis
- 4.4 Competitive analysis of major market players
- 4.5 Competitive positioning matrix
- 4.6 Key developments
  - 4.6.1 Mergers and acquisitions
  - 4.6.2 Partnerships and collaborations
  - 4.6.3 Expansion plans

## Chapter 5 Market Estimates and Forecast, By Vaccine Type, 2021 - 2034 (\$ Mn)

- 5.1 Key trends
- 5.2 Single antigen vaccine
- 5.3 Combination vaccine

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

## Chapter 6 Market Estimates and Forecast, By Age Group, 2021 - 2034 (\$ Mn)

6.1 Key trends

6.2 Pediatric

6.3 Adult

## Chapter 7 Market Estimates and Forecast, By Gender, 2021 - 2034 (\$ Mn)

7.1 Key trends

7.2 Female

7.3 Male

## Chapter 8 Market Estimates and Forecast, By End Use, 2021 - 2034 (\$ Mn)

8.1 Key trends

8.2 Hospitals

8.2.1 Public

8.2.2 Private

8.3 Specialty clinics

8.4 Other end use

## Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2034 (\$ Mn)

9.1 Key trends

9.2 North America

9.2.1 U.S.

9.2.2 Canada

9.3 Europe

9.3.1 Germany

9.3.2 UK

9.3.3 France

9.3.4 Spain

9.3.5 Italy

9.3.6 Netherlands

9.4 Asia Pacific

9.4.1 China

9.4.2 Japan

9.4.3 India

9.4.4 Australia

9.4.5 South Korea

9.5 Latin America

9.5.1 Brazil

9.5.2 Mexico

9.5.3 Argentina

9.6 Middle East and Africa

9.6.1 South Africa

9.6.2 Saudi Arabia

9.6.3 UAE

## Chapter 10 Company Profiles

10.1 Bharat Biotech

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 10.2 Biological E
- 10.3 Dynavax Technologies
- 10.4 Gilead Sciences
- 10.5 GSK
- 10.6 Merck
- 10.7 Sanofi
- 10.8 Serum Institute of India
- 10.9 Shenzhen Kangtai Biological Products
- 10.10 VBI vaccines
- 10.11 YS Biopharma

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

**Hepatitis B Vaccine Market Opportunity, Growth Drivers, Industry Trend Analysis,  
and Forecast 2025 - 2034**

Market Report | 2025-07-04 | 140 pages | Global Market Insights

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

**ORDER FORM:**

Select license	License	Price
	Single User	\$4850.00
	Multi User	\$6050.00
	Enterprise User	\$8350.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-10"/>
		Signature	

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

